Online drug research firm drugs.com today released its list of the top 100 selling drugs in the United States for the first quarter of 2012. The top five sellers include drugs from Bristol-Myers Squibb Co. (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Merck & Co. (NYSE: MRK) and Japan’s Otsuka Pharmaceutical Co. In addition, GlaxoSmithKline (NYSE: GSK), Eli Lilly & Co. (NYSE: LLY) and Abbott Laboratories (NYSE: ABT) were among the top 10 sellers.
The list:
- Plavix (BMY) — $1.62 billion in sales
- Nexium (AZN) — $1.40 billion
- Ability (Otsuka) — $1.34 billion
- Singulair (MRK) — $1.24 billion
- Seroquel (AZN) — $1.16 billion
- Advair Diskus (GSK) — $1.14 billion
- Crestor (AZN) — $1.12 billion
- Cymbalta (LLY) — $1.03 billion
- atorvastatin (generic) — $0.95 billion
- Humira (ABT) — $0.93 billion
The biggest gain compared to the fourth quarter of 2011 went to the atorvastatin generic, which saw sales rise by nearly $450,000. The generic has drawn sales from Lipitor, made by Pfizer Inc. (NYSE: PFE), which lost patent protection last year. Lipitor sales fell by more than $760,000 in the quarter to just over $840,000.
A generic version of Plavix — clopidogrel — recently hit the market, so the top of the rankings may be in for a change later this year.
Paul Ausick
The Average American Is Losing Their Savings Every Day (Sponsor)
If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4% today, and inflation is much higher. Checking accounts are even worse.
Every day you don’t move to a high-yield savings account that beats inflation, you lose more and more value.
But there is good news. To win qualified customers, some accounts are paying 9-10x this national average. That’s an incredible way to keep your money safe, and get paid at the same time. Our top pick for high yield savings accounts includes other one time cash bonuses, and is FDIC insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes and your money could be working for you.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
